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Anti-inﬂammatoryAbstract A small library of twenty-four quinoline based butenolides also known as furanones
and their nitrogen analogues was prepared by using two different aroylpropionic acids, viz.
3-(2-naphthoyl)propionic acid (3) and 3-(biphenyl-4-yl)propionic acid (4), as starting materials.
The 3-aroylpropionic acids were reacted with different 6-substituted-2-chloroquinolin-3-carbalde
hydes (2a–d) to obtain the corresponding furan-2(3H)-ones (5a–h). The puriﬁed and characterized
furanones were then converted into their corresponding 2(3H)-pyrrolones (6a–h) and N-benzyl-
pyrrol-2(3H)-ones (7a–h). The antimicrobial activities of the title compounds were evaluated against
two strains of each Gram +ve (Staphylococcus aureus and Bacillus subtilis), Gram ve bacteria
(Escherichia coli and Pseudomonas aeruginosa) and against fungal strains of Aspergillus niger and
Aspergillus ﬂavus. In vivo anti-inﬂammatory potential of the title compounds was investigated by
standard method. Majority of the compounds showed signiﬁcant antibacterial activity against both
the Gram +ve strains. Eight most potent anti-inﬂammatory compounds (5b, 5d, 5h, 6b, 7b, 7d, 7f,
7h) which exhibited >53% inhibition in edema, were also screened for their in vivo analgesic activ-
ity. All the tested compounds were found to have signiﬁcant reduction in ulcerogenic action but
only three compounds (5d, 5h and 7h) showed comparable analgesic activity to standard drug,
diclofenac. The results were also validated using in silico approach and maximum mol doc score, India.
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706 S.L. Khokra et al.was obtained for compounds 7a–h. On comparing the in vivo and in silico anti-inﬂammatory results
of synthesized compounds, N-benzyl pyrrolones (7a–h) emerged as the potent anti-inﬂammatory
agents. It was also observed that compounds that possess electron withdrawing group such as ACl
or NO2 are more biologically active.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Butenolides, also known as butyrolactones, are ﬁve membered
heterocyclic compounds occurring naturally in many medicinal
plants (Mao et al., 2011). Natural products containing buteno-
lide ring system have been known to exhibit a wide range of
useful and signiﬁcant biological actions. Chemically these are
oxidized furans, which are considered as an important scaffold
to synthesize compounds of biological and pharmaceutical
importance. In recent years, a large number of synthetic com-
pounds containing butenolide nucleus were prepared and stud-
ied for various interesting biological actions in search of potent
therapeutic agents (Lattmann et al., 2004; Rossi et al., 1998;
Hashem et al., 2014). Butenolides consist of four carbon unsat-
urated c-lactone ring and occur in numerous phytochemicals
in three different forms (Fig. 1) depending upon the relative
positions of the carbonyl group and the double bond in the
hetero ring such as 2,3-dihydrofuran-2-ones or furan-2(3H)-
ones, 2,5-dihydrofuran-2-ones or furan-2(5H)-ones and 3,2-
dihydrofuran-3-ones or furan-3(2H)-ones (Allison et al., 1992).
Furanones and their open ring (acyclic) products serve as
precursors for the syntheses of large number of physiologically
active heterocyclic compounds vis-a-vis can also be fused or
combined with other heterocyclic moieties (Allison et al.,
1992; Flower, 2003). A number of nitrogen containing hetero-
cyclic systems which exhibit promising biological activities and
are prepared from butenolides include pyrrolones, pyridazi-
nones, pyrazoles, isothiazolones, oxadiazoles, triazoles, etc
(Bekhit and Abdel-Azeim, 2004; Bailly et al., 2008; Hashem
et al., 2014). Several research studies conducted elsewhere have
shown that butenolides (furanones) possess wide spectrum of
biological activities such as antibacterial, antifungal, antiviral,
antioxidant, antimalarial, anticonvulsant, anti-inﬂammatory,
COX-II inhibition, analgesic, antitumor, and anticancer prop-
erties (Albrecht et al., 2008; Moosavi-Movahedi et al., 2003;
Levy et al., 2003; Lattmann et al., 2004; Hashem et al.,
2014). Recently, there has been a great interest in preparing
arylidene butenolides, which have a large spectrum of impor-
tant and potential biological activities (Lattmann et al., 2005;
Khan and Husain, 2002; Leite et al., 1999). The c-lactone ring
of butenolides is quite reactive and therefore employed as a
building block to construct diverse classes of nitrogen hetero-
cyclic compounds possessing signiﬁcant pharmacologicalO
O
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rms of furanone ring.activities (Black et al., 2003; Zarghi et al., 2007; Hashem
et al., 2007; Husain et al., 2005).
Quinoline ring system is present in number of bioactive nat-
ural products and quite a few are used therapeutically.
Quinolines and their synthetic derivatives are reported to exhi-
bit anti-inﬂammatory and analgesic activities (Husain et al.,
2013) in addition to other useful pharmacological activities
(Jashim Uddin et al., 2004; Pohle et al., 2001).
Biphenyl based furanones and pyrrolones show interesting
antimicrobial and anti-inﬂammatory activities (Khan and
Husain, 2002). Naproxen and Nabumetone are examples of
naphthalene containing NSAIDs which are usually indicated
in the management of pain and inﬂammatory conditions.
Also it has been reported that several other naphthalene
derivatives inhibit cyclooxygenase enzyme, block the synthesis
of inﬂammatory mediators and therefore, display good anti-
inﬂammatory activities (Harrak et al., 2007).
Prompted by these ﬁndings, and as a part of our current
research interest on furanone derivatives, we thought to pre-
pare compounds having three biological moieties in one i.e.
biphenyl and naphthalene based furanones or pyrrolones hav-
ing quinoline moiety in search of potent lead/drug molecules
for anti-inﬂammatory or antimicrobial therapy. A total of
twenty-four title compounds viz. eight furan-2(3H)-ones, eight
pyrrol-2(3H)-ones and eight N-benzyl-pyrrol-2(3H)-ones were
prepared and screened for antibacterial, antifungal, in vivo
analgesic and anti-inﬂammatory activities.2. Experimental
2.1. General
The reagents and solvents used in all experiments were
obtained from Merck (Mumbai, India), S.D. Fine (Mumbai,
India), CDH (New Delhi) and Qualigens (India). Melting
points were recorded in open end capillary tubes using MR-
VIS Visual melting point apparatus (LAB India) and are
uncorrected. The IR spectra were recorded on Hitachi 150–
200 spectrophotometer using KBr. 1H NMR spectra were
recorded on Bruker spectrospin DPX-300 MHz in CDCl3 or
DMSO using tetramethylsilane (TMS) as an internal reference.
Chemical shift (d) values are reported in parts per million
(ppm) while splitting patterns of peaks as singlets, doublet or
triplet in proton NMR spectra are indicated by abbreviations
s, d, t and m, respectively. Mass spectrometry for title com-
pounds was performed on a JEOL JMS-D 300 instrument.
Perkin-Elmer 240 analyzer was used to perform elemental
analyses (C, H, N) and was found in the range of ±0.4%
for each analyzed element. Progress of reaction was monitored
on thin-layer chromatography using silica gel G as stationary
phase in the solvent system-Toluene:Ethyl acetate:Formic acid
(5:4:1, v/v/v) or Petroleum ether:Toluene:Ethyl acetate (5:4:1,
Quinoline based furanones and their nitrogen analogues 707v/v/v) or Ethyl acetate:Hexane (3:7, v/v), and TLC spots were
visualized under the UV light.
2.2. Chemical synthesis
2.2.1. Synthesis of 4-substituted phenyl oximes (1a–d)
4-Substituted-1-phenylethanone oximes (1a–d) were synthe-
sized by reacting different substituted acetophenones
(0.1 mol) with hydroxylamine hydrochloride (0.12 mol) in the
presence of sodium acetate (0.12 mol) as per the literature
method (Alam et al., 2009).
2.2.2. Synthesis of substituted-2-chloroquinoline-3-
carbaldehydes (2a–d) (Alam et al., 2009)
A freshly distilled phosphorus oxychloride (0.35 mol) was
added dropwise with stirring to a previously cooled solution
of dimethylformamide (0.15 mol) and then oxime (1a–d)
(0.05 mol) was added in small portions. The resulting mixture
was heated at 60 C for 16 h, followed by decomposition by
pouring into ice cold water (300 mL). The mixture was contin-
uously agitated for 30 min to yield a solid product. The com-
pound so obtained was ﬁltered, dried and recrystallized from
ethyl acetate to get TLC pure compound (2a–d).
2.2.3. Synthesis of 3-(substituted aroyl) propionic acid (3,4)
3-(2-Naphthoyl) propionic acid (3) and 3-(biphenyl-4-yl) pro-
pionic acid (4) were synthesized according to the literature
method (Alam et al., 2009).
2.2.4. Synthesis of furan-2(3H)-ones (5a–h)
2.2.4.1. General procedure for the synthesis of 3-{(2-chloro-6-
substituted quinolin-3-yl) methylidene}-5-(aryl)-furan-2(3H)-
one (5a–h). (Alam et al., 2009). To equimolar quantities
(0.005 mol) of 3-substituted aroylpropionic acid (3/4) and sub
stituted-2-chloroquinoline-3-carbaldehydes (2a–d), acetic
anhydride was added to just wet the mixture (5–8 drops) and
after that 2–3 drops of triethylamine were added. The reaction
mixture was reﬂuxed brieﬂy for 10–15 min and then poured
over crushed ice with gentle stirring to obtain a colored solid
mass. The solid substance after ﬁltration was washed with
water, dried and recrystallized from methanol to furnish the
desired compounds (5a–h). The physical and spectral data of
the prepared compounds are summarized in Table 1.
2.2.5. Synthesis of pyrrol-2(3H)-ones (6a–h)
2.2.5.1. General procedure for the synthesis of 3-{(2-chloro-6-
substituted quinolin-3-yl)methylidene}-5-(aryl)-pyrrol-2(3H)-
ones (6a–h). Pyrrolones were prepared by passing the ammo-
nia gas (dry) through anhydrous solution of furanones 5a–h
(1 g) in ethanol. Ethanol was removed under vacuum at the
completion of reaction to obtain the solid product. The com-
pounds were crystallized in methanol to get the pure colored
crystals of pyrrolones 6a–h. The physical and spectral data
of 6a–h are presented in Table 2.
2.2.6. Synthesis of N-benzyl-pyrrol-2(3H)-ones (7a–h)
2.2.6.1. General procedure for the synthesis of 1-benzyl-3-{(2-
chloro-6-substituted quinolin-3-yl)methylidene}-5-(aryl)-pyy-
rol-2(3H)-ones (7a–h). A mixture of furanone 5a–h
(1.5 mmol) and benzylamine (2 mmol) in dry benzene wasreﬂuxed for 1 h. After the completion of reaction, excess ben-
zene was removed under vacuum. The solid so obtained was
washed with petroleum ether, dried in air and then reﬂuxed
for 1 h in 6 N hydrochloric acid (15 mL). A solid mass was pre-
cipitated out on cooling the mixture content which on usual
workup and crystallization in methanol yielded the desired
N-benzyl-pyrrol-2(3H)-ones 7a–h. The physical and spectral
data are shown in Table 3.
2.3. Antimicrobial studies
2.3.1. Antibacterial activity
The antibacterial activity of the title compounds was tested
against following four strains: Staphylococcus aureus (MTCC
96), Bacillus subtilis (MTCC 121), Escherichia coli (MTCC
1652) and Pseudomonas aeruginosa (MTCC 741), by standard
method (Cruickshank et al., 1975). Ciproﬂoxacin was used as
standard antibiotic for comparison of the activity. The com-
pounds showing activity at 100 lg/mL concentration were
further tested for their MIC.
2.3.2. Antifungal activity
The antifungal activity of the prepared compounds was evalu-
ated against Aspergillus niger and Aspergillus ﬂavus fungal
strains by the standard poison food technique method
(Cruickshank et al., 1975). Fluconazole was used as the stan-
dard drug for comparison purpose.
2.4. Pharmacological studies
2.4.1. Animals
Anti-inﬂammatory and analgesic activities of furanones and
their nitrogen analogues were carried out on Wistar rats and
Swiss albino mice, respectively, after getting necessary
permission of animal’s usage from Kurukshetra University
animal ethics committee (Regd. No. 563/02/a/CPCSEA).
Albino rats 160–200 g and male mice weighing 25–30 g
were housed in polypropylene cages in group of six and accli-
matized to the conditions for 48 h before the commencement
of study.
2.4.2. Anti-inﬂammatory activity
Anti-inﬂammatory activity of the title compounds was evalu-
ated by the method of Winter et al. (1962) in Wistar rats of
either sex, weighing 160–200 g. The percentage inhibition of
edema was calculated at 1 h, 2 h, 3 h and 4 h and the results
were compared with the standard drug, diclofenac.
2.4.3. Analgesic activity
Eight compounds which displayed good anti-inﬂammatory
activity (>53% inhibition) were selected for evaluation of
peripheral and central analgesic activity in mice by two meth-
ods viz. acetic acid induced writhing method and tail immer-
sion method (Seigmund et al., 1957).
2.4.3.1. Acetic acid induced constrictions method. The periph-
eral analgesic activity of selected compounds was evaluated
by acetic acid induced writhing method. Aqueous acetic acid
was used to induce writhing in Swiss Albino mice (20–30 g)
Table 1 Physical data and spectral data of 3-[(2-chloro-6-substituted-quinolin-3-yl)methylene]-5-(aryl)furan-2(3H)-one (5a–h).
R
N
ClO
O (5a-d)
R
N
ClO
O (5e-h)
Compd AR Physical data and spectral data
5a AH 3-[(2-Chloroquinolin-3-yl) methylene]-5-(naphthalene-2-yl)furan-2(3H)-one: Yield 65%; m.p. 221–222 C, Rf 0.92, IR (KBr)
cm1 1763 (C‚O), 1566 (ArC‚C), 1063 (ArCAN), 847 (ArCAH). 1H NMR (CDCl3): 6.92 (s, 1H, bH), 7.25 (s, 1H, oleﬁnic
H), 7.63–8.25 (complex m, 12H, aryl protons), MS (m/z): 383 (M+), 384 (M+ 1), 385 (M+ 2); Anal. Calcd. for
C24H14ClNO2: C, 75.10; H, 3.68; N, 3.65; Found: C, 75.22; H, 3.44; N, 3.52
5b ACl 3-[(2,6-Dichloroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)furan-2(3H)-one: Yield 57%; m.p. 245–246 C, Rf 0.88, IR
(KBr) cm1 1767 (C‚O), 1558 (ArC‚C), 1066 (ArCAN), 849 (ArCAH). 1H NMR (CDCl3): 6.60 (s, 1H, bH), 7.29 (s, 1H,
oleﬁnic H), 7.42–8.20 (complex m, 11H, aryl protons), MS (m/z): 417 (M+), 418 (M+ 1), 419 (M+ 2); Anal. Calcd. for
C24H13Cl2NO2: C, 68.92; H, 3.13; N, 3.35; Found: C, 68.75; H, 3.05; N, 3.23
5c ACH3 3-[(2-Chloro-6-methylquinolin-3-yl)methylene]-5-(naphthalene-2-yl)furan-2(3H)-one: Yield 61%; m.p 214–215 C, Rf 0.91,
IR (KBr) cm1 1759 (C‚O), 1561 (ArC‚C), 1061 (ArCAN), 852 (ArCAH). 1H NMR (CDCl3): 2.18 (s, 3H, CH3), 6.78 (s,
1H, bH), 7.22 (s, 1H, oleﬁnic H), 7.28–8.26 (complex m, 11H, aryl protons), MS (m/z): 397 (M+), 398 (M+ 1), 399 (M+ 2),
Anal. Calcd. for C25H16ClNO2: C, 75.47; H, 4.05; N, 3.52, Found: C, 75.63; H, 3.83; N, 3.44
5d ANO2 3-[(2-Chloro-6-nitroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)furan-2(3H)-one: Yield 59%; m.p 257–258 C, Rf 0.85, IR
(KBr) cm1 1774 (C‚O), 1570 (ArC‚C), 1063 (ArCAN), 857 (ArCAH). 1H NMR (CDCl3): 6.81 (s, 1H, bH), 7.28 (s, 1H,
oleﬁnic H), 7.45–8.18 (complex m, 11H, aryl protons); MS (m/z): 428 (M+), 429 (M+ 1), 430 (M+ 2) Anal. Calcd. for
C24H13ClN2O4: C, 67.22; H, 3.06; N, 6.53; Found: C, 67.05. H, 3.28; N, 6.25
5e AH 3-[(2-Chloroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)furan-2(3H)-one: Yield 63%; m.p 120–122 C, Rf 0.86, IR (KBr) cm1
1769 (C‚O), 1563 (ArC‚C), 1059 (ArCAN), 865 (ArCAH). 1H NMR (CDCl3): 6.88 (s, 1H, bH), 7.37 (s, 1H, oleﬁnic
proton), 7.53–8.23 (m, 14H, aryl protons), MS (m/z): 409 (M+), 410 (M+ 1), 411 (M+ 2). Anal. Calcd. for C26H16ClNO2:
C, 76.19; H, 3.93; N, 3.42; Found: C, 76.35; H, 4.03; N, 3.37
5f ACl 3-[(2,6-Dichloroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)furan-2(3H)-one: Yield 46%; m.p 246 C, Rf 0.76, IR (KBr) cm1
1713 (C‚O), 1518 (ArC‚C), 1038 (ArCAN), 824 (ArCAH). 1H NMR (CDCl3): 6.85 (s, 1H, bH), 7.40 (s, 1H, oleﬁnic
proton), 7.46–8.35 (m, 13H, aryl protons), MS (m/z): 444 (M+), 445 (M+ 1), 446 (M+ 2); Anal. Calcd. for C26H15Cl2NO2:
C, 70.28; H, 3.40; N, 3.15; Found: C, 70.13; H, 3.32; N, 3.09
5g ACH3 3-[(2-Chloro-6-methylquinolin-3-yl)methylene]-5-(biphenyl-4-yl)furan-2(3H)-one: Yield 58%; m.p 154 C, Rf-0.74, IR (KBr)
cm1 1752 (C‚O), 1556 (ArC‚C), 1054 (ArCAN), 829 (ArCAH). 1H NMR (CDCl3): 2.13 (s, 3H, CH3), 6.89 (s, 1H, bH),
7.33 (s, 1H, oleﬁnic proton), 7.38–8.24 (m, 13H, aryl protons), MS (m/z): 423 (M+), 424 (M+ 1), 425 (M+ 2); Anal. Calcd.
for C27H18ClNO2: C, 76.50; H, 4.28; N, 3.30; Found: C, 76.26; H, 4.18; N, 3.43.
5h ANO2 3-[(2-Chloro-6-nitroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)furan-2(3H)-one: Yield 65%; m.p. 184–186 C, Rf-0.71, IR
(KBr) cm1 1767 (C‚O), 1553 (ArC‚C), 1051 (ArCAN), 838 (ArCAH). 1H NMR (CDCl3): 6.91 (s, 1H, bH), 7.39 (s, 1H,
oleﬁnic proton), 7.46–8.31 (m, 13H, aryl protons), MS (m/z): 454 (M+), 455 (M+ 1), 456 (M+ 2); Anal. Calcd. for
C26H15ClN2O4: C, 68.65; H, 3.32; N, 6.16; Found: C, 68.43; H, 3.45; N, 6.07
708 S.L. Khokra et al.of either sex which were divided into groups of six animals in
each. The analgesic activity was calculated by using the follow-
ing formula:
%Protection ¼ fðWcWtÞ=Wcg  100
where Wc= mean number of writhing of control group, and
Wt=mean number of writhing of test group.
2.4.3.2. Tail immersion method. The Mice used in the writhing
test were again used for tail immersion method after washing
period (Seigmund et al., 1957). Mice of each group were placed
in a suitable restrainer such that their tail protrudes outside.The protruding tail (up to 5 cm) is dipped into hot water
(55 C) and the time taken by the mice to withdraw its tail
out of water is recorded as the reaction time. Readings were
taken at 1 h and 2 h after the dosing.
2.4.4. Acute ulcerogenic activity
Acute ulcerogenic studies were performed in Albino rats as per
the method of Cioli et al. (1979). The mucosal damage was
examined at the end of study and ulcerogenic potential of
the compounds was calculated by comparing the average score
of treatment group with the mean score of rats in control
group.
Table 2 Physical data and spectral data of 3-[(2-chloro-6-substituted-quinolin-3-yl)methylene]-5-(aryl)-1H-pyrrol-2(3H)-one (6a–f).
R
N
ClN
O (6a-d)
R
N
ClN
O (6e-h)
H
H
Compd AR Physical and spectral data
6a AH 3-[(2-Chloroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 78%, m.p. 280 C, Rf-0.79, IR (KBr,
cm1); 3410 (NH), 1696 (C‚O), 1582 (ArC‚C), 1033 (ArCAN), 802 (ArCAH). 1H NMR (CDCl3) d= 6.46 (s, 1H, bH),
7.08 (s, 1H, oleﬁnic H), 7.41–8.13 (complex m, 13H, 12 aryl protons + NH). MS[EI] m/z 382 (M+), 383 (M+ 1), 384
(M+ 2). Elemental Analysis.Calcd. C24H15ClN2O: C, 75.29; H, 3.95; N, 7.32; found: C, 75.42; H, 3.87; N, 7.25
6b ACl 3-[(2,6-Dichloroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 74%; m.p 205 C, Rf-0.80, IR
(KBr) cm1–3443 (NH), 1706 (C‚O), 1602 (ArC‚C), 1057 (ArCAN), 808 (ArCAH). 1H NMR (CDCl3): 6.32 (s, 1H, bH),
7.11 (s, 1H, oleﬁnic H), 7.38–8.15 (complex m, 13H, 12 aryl protons + NH); MS (m/z): 416 (M+), 417 (M+ 1), 418
(M+ 2); Anal. Calcd. for C24H14Cl2N2O: C, 69.08; H, 3.38; N, 6.71; Found: C, 68.86; H, 3.34; N, 6.84
6c ACH3 3-[(2-Chloro-6-methylquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 71%; m.p. 240 C, Rf-0.78,
IR (KBr) cm1 3388 (NH), 1683 (C‚O), 1607 (ArC‚C), 1019 (ArCAN), 801 (ArCAH). 1H NMR (CDCl3): 2.23 (s, 3H,
CH3), 6.54 (s, 1H, bH), 7.12 (s, 1H, oleﬁnic H), 7.31–8.18 (complex m, 12H, 11 aryl protons + NH); MS (m/z): 396 (M
+),
397 (M+ 1), 398 (M+ 2). Anal. Calcd. for C25H17ClN2O: C, 75.66; H, 4.32; N, 7.06; Found: C, 75.46; H, 4.27; N, 7.22
6d ANO2 3-[(2-Chloro-6-nitroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 68%; m.p. 281 C, Rf-0.73,
IR (KBr) cm1 3435 (NH), 1692 (C‚O), 1591 (ArC‚C), 1036 (ArCAN), 814 (ArCAH). 1H NMR (CDCl3): 6.63 (s, 1H,
bH), 7.22 (s, 1H, oleﬁnic H), 7.25–8.29 (complex m, 12H, 11 aryl protons + NH); MS (m/z): 427 (M+), 428 (M+ 1), 429
(M+ 2), Anal. Calcd. for C24H14ClN3O3: C, 67.38; H, 3.30; N, 9.82; Found: C, 67.45; H, 3.21; N, 9.65
6e AH 3-[(2-Chloroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 66%; m.p 148–150 C, Rf-0.76, IR (KBr)
cm1 3392 (NH), 1687 (C‚O), 1590 (ArC‚C), 1018 (ArCAN), 792 (ArCAH). 1H NMR (CDCl3): 6.28 (s, 1H, bH), 7.13 (s,
1H, oleﬁnic H), 7.15–8.29 (complex m, 15H, 14 aryl protons + NH); MS (m/z): 408 (M+), 409 (M+ 1), 410 (M+ 2); Anal.
Calcd. for C26H17ClN2O: C, 76.37; H, 4.19; N, 6.85, Found: C, 76.47; H, 4.14; N, 6.61
6f ACl 3-[(2,6-Dichloroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 70%; Rf-0.67, IR (KBr) cm
1 3451
(NH), 1689 (C‚O), 1601 (ArC‚C), 1026 (ArCAN), 813 (ArCAH). 1H NMR (CDCl3): 6.36 (s, 1H, bH), 7.12 (s, 1H, oleﬁnic
H), 7.24–8.31 (complex m, 14H, 13 aryl protons + NH); MS (m/z): 442 (M+), 443 (M+ 1), 444 (M+ 2); Anal. Calcd. for
C26H16Cl2N2O: C, 70.44; H, 3.64; N, 6.32; Found: C, 70.31; H, 3.58; N, 6.25
6g ACH3 3-[(2-Chloro-6-methylquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 72%; Rf-0.71, IR (KBr) cm
1
3441 (NH), 1696 (C‚O), 1594 (ArC‚C), 1019 (ArCAN), 788 (ArCAH). 1H NMR (CDCl3): 2.25 (s, 3H, CH3), 6.31 (s, 1H,
bH), 7.12 (s, 1H, oleﬁnic H), 7.17–8.20 (complex m, 14H, 13 aryl protons + NH); MS (m/z): 422 (M+), 423 (M+ 1), 424
(M+ 2); Anal. Calcd. for C27H19ClN2O: C, 76.68; H, 4.53; N, 6.62; Found: C, 76.54; H, 4.49; N, 6.54
6h ANO2 3-[(2-Chloro-6-nitroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 65%; Rf-0.70, IR (KBr) cm
1
3435 (NH), 1708 (C‚O), 1611 (ArC‚C), 1037 (ArCAN), 805 (ArCAH). 1H NMR (CDCl3): 6.36 (s, 1H, bH), 7.08 (s, 1H,
oleﬁnic H), 7.12–8.34 (complex m, 14H, 13 aryl protons + NH); MS (m/z): 453 (M+), 454 (M+ 1), 455 (M+ 2); Anal.
Calcd. for C26H16ClN3O3: C, 68.80; H, 3.55; N, 9.26; Found: C, 68.63; H, 3.28; N, 9.55
Quinoline based furanones and their nitrogen analogues 7092.5. Docking studies
The ligand dataset was virtually screened with the protein tar-
gets using Molegro software (MVD 4.2) and the binding
energy values were analyzed for each docked conformation
(William et al., 2008; Reyes and Kollman, 2000).
Conformations having low energy and exhibited favorable
hydrogen bonding with the amino acids side chain and its
amide nitrogen were considered (Table 7). Binding energies
of the protein–ligand interactions are of signiﬁcant importance
because they tell us how well the ligand binds to the target
macromolecule. Docking simulations of furanones against
3LN1 protein target lead to the identiﬁcation of few potentialcompounds which were evaluated based on the binding com-
patibility [docked energy (kcal/mol)] with the receptor.
3. Results and discussion
3.1. Chemistry
The title compounds were prepared as per the protocol out-
lined in Scheme 1. The present work involved clubbing of fura-
none and pyrrolones with quinoline moiety to obtain newer
effective compounds. The synthetic methodology involves the
synthesis of quinoline-3-carbaldehyde derivatives (2a–d) by
reacting N,N-dimethylformamide (DMF) with acetophenone
Table 3 Physical and spectral data of 1-benzyl-3-{(2-chloro-6-substituted quinolin-3-yl)methylidene}-5-(aryl)-1H-pyyrol-1(3H)-one
(7a–h).
R
N
ClN
O (7a-d)
R
N
ClN
O (7e-h)
Compd AR Physical and spectral data
7a AH 1-Benzyl-3-[(2-chloroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 74%; m.p. 183 C, Rf-0.87,
IR (KBr) cm1 1753 (C‚O), 1603 (ArC‚C), 1038 (ArCAN), 808 (ArCAH). 1H NMR (CDCl3): 4.89 (s, 2H, CH2), 6.48 (s,
1H, bH), 7.09–8.18 (complex m, 18H, 17 aryl protons + oleﬁnic H), MS (m/z): 472 (M+), 473 (M+ 1), 474 (M+ 2); Anal.
Calcd. for C31H21ClN2O: C, 78.72; H, 4.48; N, 5.92; Found: C, 78.52; H, 4.53; N, 5.78
7b ACl 1-Benzyl-3-[(2,6-dichloroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 70%; m.p. 168–170 C,
Rf-0.82, IR (KBr) cm
1 1748 (C‚O), 1595 (ArC‚C), 1033 (ArCAN), 812 (ArCAH) 1H NMR (CDCl3): 4.89 (s, 2H, CH2),
6.54 (s, 1H, bH), 7.09–8.18 (complex m, 18H, 17 aryl protons + oleﬁnic H), MS (m/z): 506 (M+), 507 (M+ 1), 508 (M+ 2);
Anal. Calcd. for C31H20Cl2N2O: C, 73.38; H, 3.97; N, 5.52; Found: C, 73.13; H, 3.83; N, 5.34
7c ACH3 1-Benzyl-3-[(2-chloro-6-methylquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 72%; m.p. 176 C,
Rf-0.87, IR (KBr) cm
1 1742 (C‚O), 1606 (ArC‚C), 1041 (ArCAN), 815 (ArCAH). 1H NMR (CDCl3): 2.38 (s, 3H, CH3),
4.88 (s, 2H, CH2), 6.46 (s, 1H, bH), 7.18–8.25 (complex m, 17H, 16 aryl protons + oleﬁnic H), MS (m/z): 486 (M
+), 487
(M+ 1), 488 (M+ 2). Anal. Calcd. for C32H23ClN2O: C, 78.92; H, 4.76; N, 5.75; Found: C, 78.57; H, 4.65; N, 5.67
7d ANO2 1-Benzyl-3-[(2-chloro-6-nitroquinolin-3-yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one: Yield 66%; m.p. 164–
166 C, Rf-0.78, IR (KBr) cm1 1739 (C‚O), 1611 (ArC‚C), 1046 (ArCAN), 821 (ArCAH). 1H NMR (CDCl3): 4.88 (s,
2H, CH2), 6.44 (s, 1H, bH), 7.09–8.18 (complex m, 18H, 17 aryl protons + oleﬁnic H), MS (m/z): 517 (M
+), 518 (M+ 1),
519 (M+ 2); Anal. Calcd. for C31H20ClN3O3: C, 71.88; H, 3.89; N, 8.11; Found: C, 71.78; H, 3.65; N, 8.25
7e AH 1-Benzyl-3-[(2-chloroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 63%; m.p 154–155 C, Rf-0.79,
IR (KBr) cm1 1746 (C‚O), 1592 (ArC‚C), 1037 (ArCAN), 807 (ArCAH). 1H NMR (CDCl3): 4.89 (s, 2H, CH2), 6.26 (s,
1H, bH), 7.08–8.11 (complex m, 20H, 19 aryl protons + oleﬁnic H), MS (m/z): 498 (M+), 499 (M+ 1), 500 (M+ 2), Anal.
Calcd. for C33H23ClN2O: C, 79.43; H, 4.65; N, 5.61; Found: C, 79.52; H, 4.46; N, 5.52
7f ACl 1-Benzyl-3-[(2,6-dichloroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 71%; m.p 142–144 C, Rf-
0.81, IR (KBr) cm1-1742 (C‚O), 1598 (ArC‚C), 1039 (ArCAN), 811 (ArCAH). 1H NMR (CDCl3): 4.89 (s, 2H, CH2),
6.23 (s, 1H, bH), 7.19–8.16 (complex m, 20H, 19 aryl protons + oleﬁnic H), MS (m/z): 532 (M+), 533 (M+ 1), 534 (M+ 2),
Anal. Calcd. for C33H22Cl2N2O: C, 74.30; H, 4.16; N, 5.25; Found: C, 74.47; H, 4.25; N, 5.17
7g ACH3 1-Benzyl-3-[(2-chloro-6-methylquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 71%; m.p 170 C, Rf-
0.72, IR (KBr) cm1 1737 (C‚O), 1599 (ArC‚C), 1034 (ArCAN), 796 (ArCAH). 1H NMR (CDCl3): 2.36 (s, 3H, CH3),
4.88 (s, 2H, CH2), 6.26 (s, 1H, bH), 7.03–8.12 (complex m, 20H, 19 aryl protons + oleﬁnic H), MS (m/z): 512 (M
+), 513
(M+ 1), 514 (M+ 2), Anal. Calcd. for C34H25ClN2O: C, 79.60; H, 4.91; N, 5.46; Found: C, 79.41; H, 5.14; N, 5.18
7h ANO2 1-Benzyl-3-[(2-chloro-6-nitroquinolin-3-yl)methylene]-5-(biphenyl-4-yl)-1H-pyrrol-2(3H)-one: Yield 71%; m.p. 142–144 C,
Rf-0.81, IR (KBr) cm
1 1744 (C‚O), 1613 (ArC‚C), 1046 (ArCAN), 818 (ArCAH). 1H NMR (CDCl3): 4.89 (s, 2H, CH2),
6.23 (s, 1H, bH), 7.19–8.16 (complex m, 20H, 19 aryl protons + oleﬁnic H), MS (m/z): 543 (M+), 544 (M+ 1), 545 (M+ 2),
Anal. Calcd. for C33H22ClN3O3: C, 72.86; H, 4.08; N, 7.72; Found: C, 72.63; H, 3.84; N, 7.57
710 S.L. Khokra et al.oxime (1a–d) in the presence of phosphorus oxychloride
(POCl3). The reaction proceeds via Beckmann rearrangement
followed by Vilsmeier–Haack formylation. The 3-aroyl propi-
onic acids (3,4) were prepared by Friedel–Craft acylation of
naphthalene and biphenyl with succinic anhydride.
Condensation of quinolone-3-carbaldehyde (2a–d) with 3-
aroyl propionic acid (3,4) in the presence of acetic anhydride
resulted in the formation of 3-{(2-chloro-6-substituted
quinolin-3-yl) methylidene}-5-(aryl)-furan-2(3H)-one (5a–h).
The 3-{(2-chloro-6-substituted quinolin-3-yl) methylidene}-5-
(aryl)-pyrrol-2(3H)-ones (6a–h) were prepared by reacting
furan-2(3H)-ones (5a–h) with dry ammonia in absolute etha-
nol. The 1-benzyl-3-{(2-chloro-6-substituted quinolin-3-yl)methylidene}-5-(aryl)-pyyrol-2(3H)-ones (7a–h) were obtained
by reacting furan-2(3H)-ones with benzylamine in dry benzene
to give c-ketobenzylamides, which were then lactamized in 6 N
HCl to furnish the corresponding N-benzyl-2(3H)-pyrrolones
(7a–h). The chemical structures of the title compounds were
characterized by IR, 1H NMR, Mass spectral data and are well
supported by elemental analysis.
The infrared spectral studies (IR; cm1) of furan-2(3H)-
ones 5a–h showed bands at 1774–1713 (lactone C‚O);
1570–1518 (ArC‚C), 1066–1038 (ArCAN), and 865–824
(ArCAH). IR band for Pyrrol-2(3H)-one 6a–h appeared at
3451–3388 (pyrrolone NAH), 1708–1683 (C‚O); 1611–1582
(ArC‚C) and 814–788 (ArCAH). IR spectra of N-
RCH3
O
R
CH3
NOH
R
NH2OH.HCl
DMF
POCl3
N
H
O
Cl
Ar
H
O OO
+
O
OH
Ar
O
(1a-d) (2a-d)
(3 & 4)
Anhyd. AlCl3
+
Ac2O
Triethylamine
R
N
ClO
O
Ar
R
N
ClN
O
Ar
H
R
N
ClN
O
Ar B
enz
ylam
ine
HC
l
Ammonia
(5a-h)
(6a-h)
(7a-h)
3, Ar =
4, Ar =
Scheme 1 Protocol for synthesis of title compounds.
Quinoline based furanones and their nitrogen analogues 711Benzylpyrrol-2(3H)-ones 7a–h gave bands at 1753–1737 (lac-
tone C‚O); 1613–1592 (ArC‚C), 1046–1033 (ArCAN), and
821–796 (ArCAH). In 1H NMR spectra, signal at around d
6.6 indicates the formation of furan ring. The absence of alde-
hydic proton and presence of alkenic proton further indicate
the conversion of aldehydic group to the desired compound.
The d values were calculated using incremental parameters
for the hydrogen (semicyclic double bond) which indicated
an (E)-conﬁguration. The Mass spectra of the title compounds
displayed M+ peak in reasonable intensities. The molecular
ion peak and isotopic peaks and fragment peaks were quite
clear due to the presence of chlorine atom(s) in all the title
compounds. The physical and spectral data of all the synthe-
sized compounds (5a–h, 6a–h and 7a–h) are presented in
Tables 1–3.
3.2. Antimicrobial activity
All the three series of synthesized compounds (5a–h, 6a–h and
7a–h) were screened for the antimicrobial activity against few
selected bacterial and fungal strains.
3.2.1. Antibacterial and antifungal activity
All the screened compounds showed variable antimicrobial
activity against the tested microbes. The results of antibacterialtesting indicate that four pyrrolone compounds 6b, 6d, 6f and
6h are highly active against S. aureus and three compounds 6b,
6d and 6f against B. subtilis, with MIC 6.25 lg/mL. The most
potent antibacterial compounds among furanones and N-
benzyl pyrrolones against S. aureus were found to be 5b, 5d,
5f and 7f, respectively with MIC of 12.5 lg/mL. However,
compounds 5a, 5c, 5g, 7e and 7g did not show any inhibition
against the gram negative bacteria E. coli and P. aeruginosa.
The most potent compounds against E. coli and P. aeruginosa
were observed to be 5d, 6d, 7b and 6d, respectively with a MIC
of 12.5 lg/mL. Compounds 6d and 6f also exhibited signiﬁcant
antifungal activity against A. niger with MIC 6.25 lg/mL.
Their activity was at par with the standard drugs, ciproﬂoxacin
or ﬂuconazole which also had MIC of 6.25 lg/mL. In general,
majority of the tested compounds were found to be less active
against the E. coli, P. aeruginosa and A. ﬂavus. Results of
antibacterial and antifungal activity are summarized in
Table 4.
A closer look at the results revealed that the title com-
pounds possess better antifungal activity as compared to
antibacterial activity. Among all the prepared compounds,
6d and 6f were found to be the most promising antibacterial
and antifungal agents. It was interesting to note that substitu-
tion of oxygen atom with the nitrogen i.e. converting furans
into corresponding pyrrolones, signiﬁcantly enhances the
antimicrobial activity; however, introduction of benzylamine
Table 4 Antibacterial and antifungal activity (MIC, lg/mL) of synthesized compounds.
Compd Antibacterial activity Antifungal activity
S. aureus E. coli P. aeruginosa B. subtilis A. niger A. ﬂavus
5a 50 – – 50 50 –
5b 12.5 25 50 12.5 25 50
5c 25 – – 50 50 >100
5d 12.5 12.5 25 25 25 25
5e 25 – – 50 25 50
5f 12.5 50 >100 25 25 25
5g 25 – – 50 50 50
5h 25 50 – >100 25 25
6a 25 – 50 25 25 25
6b 6.25 50 50 6.25 12.5 12.5
6c 12.5 – 50 12.5 25 12.5
6d 6.25 12.5 12.5 6.25 6.25 12.5
6e 12.5 – 50 50 50 25
6f 6.25 50 25 6.25 6.25 12.5
6g 25 50 50 12.5 25 12.5
6h 6.25 25 25 12.5 25 25
7a 50 25 – >100 50 >100
7b 25 12.5 >100 25 50 25
7c 25 50 – 50 50 25
7d 25 25 >100 25 25 50
7e 50 – – – 50 >100
7f 12.5 25 50 12.5 25 50
7g 25 – – 50 25 50
7h 25 50 50 – 50 >100
Standard-1a 6.25 6.25 6.25 nt nt Nt
Standard-2a Nt Nt Nt 6.25 6.25 6.25
 Indicates microbes are resistant to the compounds >100 lg/mL; nt = not tested.
a Standard-1 = Ciproﬂoxacin, Standard-2 = Fluconazole; MIC =minimum inhibitory concentration.
N
R
ClX
Ar
O
X= O, NH, -N-CH2-Ph
Ar =
Quinoline ring
furanone /pyrrolone
or benzylpyrrolone ring
Naphthyl/biphenyl
R= H, -Cl, -CH3, -NO2
For maximum activity, R must be an electron 
withdrawing group i.e. -Cl or -NO2
Required for binding interactions with receptor
provides hydrophobicity
Bioactive moeity
Figure 2 General structure of synthesized compounds.
712 S.L. Khokra et al.moiety in place of oxygen atom (benzylpyrrolones) in the fura-
none ring leads to decreased antimicrobial activity. This
change in activity may be due to proton donor capacity of
pyrrolones.
Thus, based on the above results, the following structure
activity relationship (SAR) can be proposed for the synthe-
sized compounds (Fig. 2):1. Presence of a chloro group on the quinoline nucleus with
attached biphenyl ring was found to increase activity of
pyrrolone toward inhibition of S. aureus and B. subtilis.
2. Presence of N-benzyl pyrrolone with attached biphenyl ring
and quinoline ring was found to be highly active. But any
substitution in quinoline ring at 6-position causes decrease
in activity.
Quinoline based furanones and their nitrogen analogues 7133. Presence of a chloro group on the quinoline nucleus with
attached naphthalene ring was found to increase activity
of pyrrolone toward inhibition of A. niger and A. ﬂavus.
3.3. Anti-inﬂammatory activity
The results of anti-inﬂammatory activity presented in Table 5
showed that furanones (5a–h) inhibited carrageenan induced
edema from 56% to 63%, pyrrolones (6a–h) 36–53%,
N-benzyl pyrrolones (7a–h) 40–71% in comparison with the
standard diclofenac, 92%. Compound 3-[(2-Chloro-6-nitroqui
nolin-3-yl)methylene]-5-(biphenyl-4-yl)furan-2(3H)-one (5h)
among furanones (63% inhibition), 6b among pyrrolones
(53% inhibition) and 1-benzyl-3-[(2-chloro-6-nitroquinolin-3-
yl)methylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one (7d)
among N- benzyl pyrrolones (71% inhibition) were observed
to be the most potent compounds. Thus, it could be concluded
that furanones are potent anti-inﬂammatory agents and substi-
tution of oxygen atom of furanone ring with -NH-(pyrrolone)
leads to markedly decreased anti-inﬂammatory activity, while
replacement by benzylamine moiety (N-benzyl pyrrolone)
enhanced the anti-inﬂammatory action (Table 5). Thus, it
could be concluded that to exhibit the potent anti-
inﬂammatory activity, nitrogen atom of pyrrolone ring should
be tertiary. Among 1-benzyl-2(3H)-Pyrrolones (7a–h), the
maximum anti-inﬂammatory activity was shown by 7d and
closely followed by 1-benzyl-3-[(2,6-dichloroquinolin-3-yl)me
thylene]-5-(naphthalene-2-yl)-1H-pyrrol-2(3H)-one 7b withTable 5 Anti-inﬂammatory activity of the title compounds (5a–h, 6
Compound % Inhibition ± SEMb
After 1 h After 2 h
Control – –
Standard 84 ± 0.02** 90 ± 0.0
5a 67 ± 0.14** 62 ± 0.1
5b 74 ± 0.18** 67 ± 0.0
5c 69 ± 0.12** 66 ± 0.2
5d 79 ± 0.12** 61 ± 0.1
5e 63 ± 0.09* 60 ± 0.2
5f 63 ± 0.13** 58 ± 0.2
5g 67 ± 0.12** 62 ± 0.1
5h 73 ± 0.08** 58 ± 0.1
6a 64 ± 0.06* 53 ± 0.1
6b 62 ± 0.09* 66 ± 0.1
6c 32 ± 0.02 55 ± 0.2
6d 58 ± 0.25* 60 ± 0.2
6e 38 ± 0.21 48 ± 0.2
6f 48 ± 0.13 63 ± 0.2
6g 52 ± 0.08* 48 ± 0.2
6h 58 ± 0.19* 58 ± 0.0
7a 52 ± 0.13* 62 ± 0.2
7b 84 ± 0.06** 74 ± 0.2
7c 78 ± 0.12** 71 ± 0.2
7d 83 ± 0.06** 73 ± 0.1
7e 78 ± 0.12** 51 ± 0.1
7f 84 ± 0.12 74 ± 0.1
7g 69 ± 0.03** 54 ± 0.1
7h 36 ± 0.13 65 ± 0.2
Data are arranged as mean ± SEM ANOVA followed by Dunnet’s t tes71% and 70% inhibition respectively. The other two com-
pounds, 1-Benzyl-3-[(2,6-dichloroquinolin-3-yl)methylene]-5-(
biphenyl-4-yl)-1H-pyrrol-2(3H)-one 7h and 1-Benzyl-3-[(2-chl
oro-6-nitroquinolin-3-yl) methylene]-5-(biphenyl-4-yl)-1H-pyr
rol-2(3H)-one 7f also showed good inhibition of 69% and
64% respectively.
3.4. Analgesic activity
A total of eight test compounds (5b, 5d, 5h, 6b, 7b, 7d, 7f, 7h)
displaying good inhibition of rat paw edema was selected for
further investigation of their analgesic and ulcerogenic actions.
Acetic acid induced writhing method and tail-immersion
method were used to evaluate peripherally and centrally medi-
ated analgesic effects of the selected compounds. The results of
central analgesic activity by tail immersion method indicated a
gradual increase in reaction time at 1 h and 2 h, respectively
(Table 6). The tested compounds showed reaction time of
1–8–5.5 min at 1 h while it was much higher at 2 h (3.4–
6.5 min). The compounds 5d, 5h and 7h showed very signiﬁ-
cant analgesic activity (4.4, 4.3 and 5.5 min) comparable to
that of standard at 1 h (8.2 min) while the compounds 5d,
5h, 7f and 7h also showed good activity (6.5, 6.2, 6.2 and
6.4 min) at 2 h in tail immersion method. It was interesting
to note that 5d, 5h, 7f and 7h were also found to be the most
potent peripheral acting analgesic agents (Table 6), suggesting
that these compounds act both peripherally and centrally to
abolish pain. The percent protection against the acetic acid
induced constrictions for 5d, 5h, 7f and 7h was in the rangea–h and 7a–h).
After 3 h After 4 h
– –
3** 95 ± 0.02** 92 ± 0.03**
1** 46 ± 0.26 57 ± 0.27**
6** 39 ± 0.29 59 ± 0.13**
5** 47 ± 0.17 59 ± 0.12**
5** 56 ± 0.25* 59 ± 0.21**
2** 53 ± 0.18 59 ± 0.12**
1** 53 ± 0.17 58 ± 0.12**
1** 46 ± 0.33 56 ± 0.06**
5** 50 ± 0.13 63 ± 0.12**
8** 49 ± 0.10 36 ± 0.32
8** 53 ± 0.17 53 ± 0.18*
2** 47 ± 0.24 42 ± 0.20
2** 29 ± 0.16 48 ± 0.15*
1** 44 ± 0.33 35 ± 0.32
7** 25 ± 0.34 42 ± 0.20
4** 25 ± 0.17 36 ± 0.19
5** 50 ± 0.18 48 ± 0.15*
7** 28 ± 0.34 57 ± 0.13**
1** 70 ± 0.23* 70 ± 0.21**
8** 57 ± 0.25* 61 ± 0.21**
5** 66 ± 0.26 71 ± 0.22**
1** 44 ± 0.08 41 ± 0.08
9** 63 ± 0.14* 64 ± 0.21**
4** 30 ± 0.20 40 ± 0.16
4** 58 ± 0.34* 69 ± 0.15**
t where *p< 0.05; **p< 0.01.
Table 6 Analgesic and ulcerogenic activity of compounds 5b, 5d, 5h, 6b, 7b, 7d, 7f and 7h.
Compound Central analgesic activity [tail immersion
(reaction time in min)]
Peripheral analgesic activity
(writhing test)
Ulcerogenic activity
(severity index)
1 h 2 h No. of writhing % Protection
Control 1.4 ± 0.2 2.8 ± 0.2 42 ± 11.6 0 0.00 ± 0.00
Diclofenac 8.2 ± 0.2** 8.8 ± 0.2** 4.2 ± 1.0** 90 0.86 ± 0.28
5b 3.2 ± 0.2* 4.4 ± 0.5 26.2 ± 4.1 37.61 0.33 ± 0.35*
5d 4.4 ± 0.6** 6.5 ± 0.2 * 6.0 ± 2.2** 85.71 0.30 ± 0.31*
5h 4.3 ± 0.4** 6.2 ± 1.5* 7.6 ± 2.3** 81.9 0.40 ± 0.36
6b 1.8 ± 0.2 4.2 ± 0.6 13.8 ± 4.4* 67.14 0.43 ± 0.33
7b 2.4 ± 0.3 3.4 ± 0.2 25.4 ± 4.8 39.52 0.36 ± 0.35*
7d 3.2 ± 0.4* 5.4 ± 1.9 21.0 ± 10.0* 50 0.40 ± 0.32
7f 3.2 ± 0.2* 6.2 ± 1.5* 12.8 ± 3.8** 69.52 0.53 ± 0.12
7h 5.5 ± 0.3** 6.4 ± 0.3* 10.4 ± 3.7** 75.23 0.30 ± 0.53*
Data are arranged as mean ± SEM ANOVA followed by Dunnet’s t test where *p< 0.05; **p< 0.01.
714 S.L. Khokra et al.of 69.52–85.71%, which was quite close to the standard drug
diclofenac (90%). All these compounds possess electron with-
drawing groups i.e. Cl and NO2 in the quinoline ring. It was
also observed that 5d exhibited the most powerful analgesic
activity by peripheral and central mechanism and it is a fura-
none derivative containing a naphthyl ring at position 5 in con-
trast to other three compounds that possess a biphenyl ring.
Although, compound 6b, a pyrrolone derivative, displayed
moderate activity by tail immersion method it showed
67.14% protection in acetic acid induced writhing model.
3.5. Acute ulcerogenic test
Results of severity index (ulcerogenic activity) of selected eight
compounds indicated better tolerability and safer gastrointesti-
nal proﬁle in contrast to the standard drug diclofenac.
Compounds 5d and 7h appeared to be the least toxic
(0.30 ± 0.31 and 0.30 ± 0.53) as compared to diclofenac
(0.86 ± 0.28). The result indicates that compounds were less
toxic in terms of ulcerogenicity as compared to standard
NSAID (Table 6).Figure 3 Binding mode of Compound 7h into COX-2 (Maximum
interaction between (‚O of pyrrolone) and N(Arg 95) of distance 3.13.6. Docking studies
The results of docking against COXII (PDB3LN1) are listed in
Table 7. Docking scores of almost all synthesized compound
were greater than the internal ligand value. The docking scores
of tested compounds range between 104.82 and 160.96. The
maximum number of hydrogen bond interactions shown by
tested compounds was 6 comparable to internal ligand interac-
tion values i.e., 9. The compounds which showed maximum
docking score values are 7h (160.96) (Fig. 3), 7f (138.27),
and 7g (137.53) in comparison with internal ligand value
(86.29) while the compounds that showed maximum interac-
tion with receptor residues are 5d (6) (Fig. 4), 5h (5) and 6d (6).
The binding mode of standard, 7h and 5d into the COX 2 is
illustrated in Figs. 3–5. From the docking results (Table 7)
for anti-inﬂammatory activity it was observed that N-benzyl
pyrrolones showed maximum mol dock score in comparison
with pyrrolones, it may be due to increase in hydrophobicity
and due to substitution of hydrogen atom of pyrrolone with
benzyl group. On comparing the in vivo and in silico activity
result of synthesized compounds, it was observed that themol dock score = 160.96) shows only one hydrogen bond
1 A˚.
Figure 4 Binding mode of Compound 5d into COX-2 (Maximum number of hydrogen bond interaction = 6). It has docking score
130.34 and forms 6 hydrogen bonds as shown by blue dotted lines showing 6 hydrogen bond interactions, two between N of NO2 , one
with N(Arg 95) of distance 3.42 A˚ other with N(Arg 95) of distance 3.35 A˚, two with O of NO2, both with N(Arg 95) of distance 2.74 A˚
and 2.72 A˚, respectively, and other two between (‚O, of furanone) with O(Asp 254) of distance 3.10 and 3.10 A˚, respectively.
Figure 5 Binding mode of standard into COX-2 with Moldock score 86.29 and 9 hydrogen bond interactions, three between 4-OH of
pyranose, one with N(Trp531) of distance 2.60 A˚, second with O(Glu 31) of distance 2.51, third with O(Glu 350) of distance 3.44 A˚, fourth
between 3-OH of Pyranose and O(Glu 350) of distance 3.42 A˚, two between 5-OH(Pyranose) and O(Phe 347) of distance 2.46 A˚ other with
O(Asn 546) of distance 3.20 A˚, three between O(CH2OH), one with O(Phe 347) of distance 3.09 A˚, other with N(Lys 328) and O(Asn 546)
of distance 3.15 A˚ and 3.09 A˚, respectively.
Quinoline based furanones and their nitrogen analogues 715whole series of N-benzyl pyrrolones (7a–h) was most effective
as anti-inﬂammatory agents as they exhibited maximum inhi-
bition in edema volume and maximum mol dock score,
respectively.
4. Conclusion
A total of 24 new quinoline derivatives containing ﬁve
membered heterocyclic ring viz. furan-2(3H)-ones (5a–h),pyrrol-2(3H)-ones (6a–h) and N-benzyl-pyrrol-2(3H)-ones
(7a–h) was designed and synthesized. In vivo biological testing
results indicated some of the compounds to possess signiﬁcant
anti-inﬂammatory and analgesic activities with lesser GI toxi-
city. N-Benzyl-pyrrol-2(3H)-ones (7a–h) exhibited better anti-
inﬂammatory activity than furan-2(3H)-ones and pyrrol-
2(3H)-ones. Tested compounds also showed less GI toxicity
and better tolerability than the standard drug diclofenac.
Among the newer derivatives, four compounds 5d, 5h, 7f and
Table 7 Docking studies of the synthesized compounds (5a–h, 6a–h and 7a–h).
Compound no. Mol dock score No. of interaction Ligand atom PDB atom Distance (A˚)
Standard (PDB3LN2) 86.29 9 O of 4-OH(pyranose) N(Trp 531) 2.60
O of 4-OH(pyranose) O(Glu 31) 2.51
O of 4-OH(pyranose) O(Glu 350) 3.44
3-OH O(Glu 350) 3.42
5-OH O(Asn 546) 3.20
5-OH O(Phe 347) 2.46
O(CH2OH) O(Phe 347) 3.09
O(CH2OH) N(Lys 328) 3.15
O(CH2OH) O(Asn 546) 3.09
5a 110.78 2 O(furanone) N(Lys 41) 3.38
N(Cys 44) 2.76
5b 131.18 3 ‚O(furanone) N(Lys 239) 3.09
O(Asp253) 2.54
O(Asp 253) 3.08
5c 104.82 3 ‚O(furanone) O(Thr255) 3.29
(Asp254) 3.21
(Lys 229) 3.10
5d 120.34 6 N(NO2) N(Arg 95) 3.41
O(NO2) N(Arg95) 2.74
O(NO2) N(Arg 95) 2.72
O(NO2) N(Arg 95) 3.34
N(NO2) O(Asp 254) 3.10
‚O(furanone) O(Asp 254) 3.10
5e 113.38 1 ‚O(furanone) N(Lys 239) 2.61
5f 112.40 3 O(furanone) N(Lys 41) 3.34
‚O(furanone) N(Thr 45) 3.55
‚O(furanone) N(Cys 44) 2.67
‚O(furanone) O(Asp 43) 3.33
5g 113.65 3 O(furanone) N(Lys 41) 3.26
‚O(furanone) O(Asp 43) 3.42
‚O(furanone) N(Cys44) 2.62
5h 123.80 5 ‚O(furanone) O(Asp 254) 2.86
O(NO2) O(Asp 254) 2.95
O(NO2) N(Arg 95) 2.68
O(NO2) N(Arg 95) 3.82
N(Arg 95) 3.19
6a 113.41 2 N(Pyrrolone) O(Cys 42) 3.26
‚O(Pyrrolone) N(Cys 44) 2.73
6b 118.08 3 N(Quinoline) O(Glu 332) 3.14
‚O(Pyrrolone) O(Ser 549) 2.67
N(Pyrrolone) O(Asp 254) 2.83
6c 116.86 2 ‚O(Pyrrolone) N(Cys 44) 2.77
N(Cys 42) 3.32
6d 109.29 6 N(NO2) N(Lys 328) 3.29
O(NO2) N(Arg 95) 3.10
O(NO2) N(Lys 328) 2.88
N(Pyrrolone) N(glu 332) 3.37
N(Pyrrolone) O(Asp 254) 3.51
N(Pyrrolone) O(Asp254) 2.72
‚O(Pyrrolone) O(Ser 549) 3.05
6e 113.15 1 ‚O(Pyrrolone) N(Lys 239) 2.61
6f 116.74 1 ‚O(Pyrrolone) N(Lys 239) 2.60
6g 117.22 1 ‚O(Pyrrolone) N(Lys239) 2.61
6h 115.98 1 ‚O(Pyrrolone) N(lys 328) 3.48
7a 129.12 2 N(Quinoline) O(Lys 253) 3.56
‚O(Pyrrolone) N(Lys 239) 3.25
7b 126.69 1 N(Quinoline) O(His 228) 3.32
7c 128.274 1 N(Quinoline ring) O(Ser 549) 2.98
7d 134.12 1 O(NO2) N(Try531) 3.07
7e 131.263 1 ‚O(Pyrrolone) N(Lys 239) 2.60
7f 138.27 1 ‚O(Pyrrolone) N(Arg 95) 3.52
7g 137.53 1 ‚O(Pyrrolone) N(Arg 95) 3.53
7h 160.96 1 ‚O(Pyrrolone) N(Arg 95) 3.11
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Quinoline based furanones and their nitrogen analogues 7177h emerged as lead compounds. Further detailed studies are
needed to conﬁrm the potential of the furanone and N-
benzyl-pyrrolone derivatives in anti-inﬂammatory therapy.
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